Relative antifertility activity of three vaginal contraceptive products in the rabbit: Relationship to in vitro data
1976; Elsevier BV; Volume: 13; Issue: 4 Linguagem: Inglês
10.1016/s0010-7824(76)80033-9
ISSN1879-0518
AutoresRoger E. Homm, G. E. Doscher, E.J. Hummel, Forrest C. Greenslade,
Tópico(s)Rabbits: Nutrition, Reproduction, Health
ResumoThree types of vaginal contraceptive preparations were used to investigate the feasibility of utilizing the rabbit as a model for the study of vaginal contraceptives. DELFEN * TRADEMARK of Ortho Pharmaceutical Corporation, Raritan, New Jersey Contraceptive Foam, DELFEN Contraceptive Cream and PRECEPTIN * TRADEMARK of Ortho Pharmaceutical Corporation, Raritan, New Jersey Contraceptive Gel and corresponding vehicle preparations were administered intravaginally to rabbits. Following mating, the reduction in mean implant number was used as an index of contraceptive potency. Dose response curves indicated that the contraceptive potency rank was DELFEN Contraceptive Foam>DELFEN Contraceptive Cream>PRECEPTIN Contraceptive Gel (ED50s = 0.017, 0.39 and 2.8 ml, respectively). The ED50s for the corresponding vehicles were 12.7, 2.1 and 4.5 ml. The relationships of these in vivo data to in vitro end points were also studied using rabbit and human semen. In a titration test, one gram of DELFEN Contraceptive Foam, DELFEN Contraceptive Cream or PRECEPTIN Contraceptive Gel immobilized sperm contained in 121, 25 and 10 ml of rabbit semen, respectively, whereas sperm contained in 1.6, 8.7 and 6.4 ml were immobilized by the corresponding vehicles. Human sperm were found to be more susceptible than rabbit sperm to immobilizing agents contained in these products. The rabbit does appear to provide a model for the in vivo evaluation of relative potencies of vaginal contraceptive preparations. *TRADEMARK of Ortho Pharmaceutical Corporation, Raritan, New Jersey
Referência(s)